Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of TAS0313 in solid tumors, recurrent glioblastoma, and urothelial carcinoma
jRCT2080223768Phase 2Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jan 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of TAS0313 and pembrolizumab in Nonhematologic neoplasms, glioblastoma (GBM) and transitional cell carcinoma (TCC) (4 cohorts), sponsored by Taiho Pharmaceutical Co., Ltd. Started Jan 2018; status: completed.
02
Drugs
TAS0313pembrolizumab
03
Conditions
Nonhematologic neoplasmsglioblastoma (GBM)transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on jRCT2080223768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223768.